Mereo BioPharma Group PLC ADR (MREO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has a cash flow conversion efficiency ratio of -0.127x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.31 Million) by net assets ($34.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mereo BioPharma Group PLC ADR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Mereo BioPharma Group PLC ADR - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mereo BioPharma Group PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Donkeyrepublic Holding AS
CO:DONKEY
|
0.022x |
|
Mangalam Organics Limited
NSE:MANORG
|
0.034x |
|
Heidelberger Beteiligungsholding AG
F:IPOK
|
N/A |
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
-0.004x |
|
Thai Solar Energy Public Company Limited
BK:TSE
|
0.026x |
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
Promateris SA
RO:PPL
|
N/A |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group PLC ADR from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Mereo BioPharma Group PLC ADR stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $40.92 Million | $-30.97 Million | -0.757x | -40.56% |
| 2024-12-31 | $60.97 Million | $-32.83 Million | -0.539x | -28.79% |
| 2023-12-31 | $50.54 Million | $-21.13 Million | -0.418x | +55.97% |
| 2022-12-31 | $51.40 Million | $-48.82 Million | -0.950x | -1498.58% |
| 2021-12-31 | $119.01 Million | $-7.07 Million | -0.059x | -103.15% |
| 2020-12-31 | $-20.47 Million | $-38.62 Million | 1.887x | +267.05% |
| 2019-12-31 | $53.33 Million | $-60.22 Million | -1.129x | -59.95% |
| 2018-12-31 | $32.77 Million | $-23.14 Million | -0.706x | -37.23% |
| 2017-12-31 | $62.48 Million | $-32.15 Million | -0.515x | -48.83% |
| 2016-12-31 | $79.26 Million | $-27.40 Million | -0.346x | -424.01% |
| 2015-12-31 | $101.54 Million | $-6.70 Million | -0.066x | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more